Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature Communications (2)
Nature (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (3)

Subject Check one or more subjects to show results from those subjects only.

Biochemistry
Biophysics
Cancer
Drug discovery
Immunology
Microbiology
Pathogenesis
Structural biology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–3 of 3 results

Advanced filters: Author: Hoangdung Ho Clear advanced filters

Structural basis for dual-mode inhibition of the ABC transporter MsbA

Crystal structures of the ABC transporter MsbA in complex with two selective small-molecule antagonists reveal an unprecedented allosteric mechanism of inhibition.

Hoangdung Ho
Anh Miu
Christopher M. Koth
Research02 May 2018
Nature

Volume: 557, P: 196-201
Structure of the core human NADPH oxidase NOX2

NADPH oxidase NOX2 produces superoxide, a reactive oxygen species essential in innate immunity. Here, the authors reveal the structure of the NOX2 core, rationalize disease-causing mutations, and suggest avenues for selective NOX2 pharmacological modulation.

Sigrid Noreng
Naruhisa Ota
James T. Koerber
ResearchOpen Access14 Oct 2022
Nature Communications

Volume: 13, P: 1-11
Structural basis of antibody inhibition and chemokine activation of the human CC chemokine receptor 8

CCR8 is a promising target in cancer immunotherapy. Here, authors generated mAb1, an antagonist antibody against CCR8 and determined structures of CCR8 in complex with mAb1 or the agonist CCL1, providing insights into CCR8 inhibition and activation.

Dawei Sun
Yonglian Sun
Matthieu Masureel
ResearchOpen Access01 Dec 2023
Nature Communications

Volume: 14, P: 1-13